Valuation : Immatics N.V.

Market Cap 1.29B 1.11B 1.04B 953M 1.79B 123B 1.8B 12.37B 4.81B 62.32B 4.85B 4.74B 206B P/E 2026 *
-4.47x
P/E 2027 * -4.49x
Enterprise Value 1.01B 866M 813M 742M 1.39B 95.68B 1.4B 9.63B 3.75B 48.52B 3.78B 3.69B 161B EV / Sales 2026 *
21.6x
EV / Sales 2027 * 24.1x
Free-Float
77.39%
Yield 2026 *
-
Yield 2027 * -
1 day-0.37%
1 week+8.40%
Current month+8.78%
1 month+8.78%
3 months-15.44%
6 months-4.27%
Current year-10.29%
1 week 8.97
Extreme 8.97
9.89
1 month 8.37
Extreme 8.37
9.98
Current year 8.17
Extreme 8.17
11.94
1 year 5.05
Extreme 5.05
12.41
3 years 3.3
Extreme 3.3
13.77
5 years 3.3
Extreme 3.3
16.3
10 years 0
Extreme 0
18.42
Manager TitleAgeSince
Chief Executive Officer 51 01/01/2019
Director of Finance/CFO 57 01/10/2025
Chief Tech/Sci/R&D Officer - 01/01/2025
Director TitleAgeSince
Director/Board Member 51 01/07/2020
Chairman 70 01/10/2012
Director/Board Member 72 01/07/2020
Date Insider Type Main position Quantity % Market Cap. Importance
26/8/26
Perceptive Advisors LLC
BuyCompany 863,060 0.6436%
18/3/26 Other

Chief Financial Officer

350,000 0.2611%
18/3/26 Other

Head of Human Resources

211,000 0.1574%
Change 5-day change 1-year change 3-year change Capi.($)
-0.37%+8.40%+76.40%-20.44% 1.29B
-1.66%-4.96%+49.84%+88.43% 69.54B
-2.19%+1.32%+44.54%+88.38% 64.97B
-3.57%-4.24%+47.11%+5.60% 26.51B
+1.59%-3.15%-17.36%+448.52% 25.89B
-0.79%-10.14%+0.75%-16.17% 25.64B
-9.71%-0.36%+245.87%+377.68% 20.22B
-1.58%+0.47%+29.35%-19.62% 19.98B
-3.36%-7.58%+9.47%+535.81% 15.69B
-0.03%-0.02%+46.69%+143.59% 13.49B
Average -2.17%-2.75%+53.27%+163.18% 28.32B
Weighted average by Cap. -2.16%-3.46%+48.06%+144.04%

Financials

2026 *2027 *
Net sales 46.54M 40.07M 37.62M 34.34M 64.52M 4.43B 64.98M 446M 173M 2.25B 175M 171M 7.43B 39.58M 34.08M 32M 29.21M 54.87M 3.77B 55.27M 379M 148M 1.91B 149M 145M 6.32B
Net income -287M -247M -232M -212M -398M -27.35B -401M -2.75B -1.07B -13.87B -1.08B -1.06B -45.91B -310M -267M -250M -229M -429M -29.46B -432M -2.97B -1.15B -14.94B -1.16B -1.14B -49.47B
Net Debt -286M -246M -231M -211M -397M -27.23B -400M -2.74B -1.07B -13.81B -1.07B -1.05B -45.72B -339M -292M -274M -250M -470M -32.23B -473M -3.24B -1.26B -16.34B -1.27B -1.24B -54.11B
Logo Immatics N.V.
Immatics N.V. is a clinical-stage biopharmaceutical company. The Company is primarily engaged in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics.PRAME is a target expressed approximately 50 cancers. Its PRAME franchise includes approximately three product candidates, two therapeutic modalities and three combination therapies that target PRAME: anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy, IMA203CD8 PRAME cell therapy, IMA402 PRAME bispecific as monotherapy, in combination with immune checkpoint inhibitors, in combination with IMA401 MAGEA4/8 bispecific as well as anzu-cel in combination with Moderna’s PRAME mRNA designed to enhance cell therapy. The Company has approximately two technology platforms for target and T Cell Receptor (TCR) discovery.
Employees
704
Date Price Change Volume
01/09/26 USD 9.420 -0.32% 318,928
28/08/26 USD 9.450 +0.96% 1,094,155
27/08/26 USD 9.360 -0.74% 743,417
26/08/26 USD 9.430 +2.06% 777,957
25/08/26 USD 9.240 +6.33% 1,062,766
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
9.450USD
Average target price
17.63USD
Spread / Average Target
+86.60%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMTX Stock